Sars-CoV2 Clinical Trial
Official title:
Incidence of COVID-19 Test Conversion in Post-surgical Patients
Verified date | May 2020 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The current Sars-CoV-2 (COVID-19) pandemic has created major changes in how physicians perform routine healthcare for our patients, including elective and non-elective surgical procedures. Beginning on March 16th, 2020 Northwell Health postponed all elective surgeries. As the incidence of COVID-19 cases begins to decrease and hospital volume improves we need to ensure the safety of our patients planning surgical procedures. However, at this time there is a scarcity of data regarding the COVID-19 test conversion rate in surgical patients. Our goal is to determine the COVID-19 test conversion rate in these patients to better guide strategies for restarting surgical care in a large-scale pandemic. Patients will be routinely tested with serology and PCR for COVID-19 24-48 hours prior to their scheduled surgery. Those who provide informed consent will be re-tested 12-16 days after discharge from the hospital to determine any potential nosocomial infection rate. Patients will also answer a few questions during their retest to allow the study team to gauge exposure risk postoperatively after leaving the hospital.
Status | Completed |
Enrollment | 111 |
Est. completion date | October 4, 2020 |
Est. primary completion date | October 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients of any ethnic background undergoing an elective surgical procedure with a minimum of 24-hour hospital admission. 2. Age =18. 3. Written Voluntary Informed Consent. Exclusion Criteria: 1. Patients age < 18 years. 2. Prior documented COVID-19 Infection. 3. Current hospital inpatient prior to procedure. 4. Person Under Investigation for COVID-19 infection. 5. Current use of antiviral medications. 6. Severe or uncontrolled, concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.) . 7. Documented immunodeficiency. 8. Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry. 9. Outpatient procedures with planned same-day discharge. |
Country | Name | City | State |
---|---|---|---|
United States | North Shore University Hospital | Manhasset | New York |
United States | Long Island Jewish Medical Center | New Hyde Park | New York |
Lead Sponsor | Collaborator |
---|---|
Northwell Health |
United States,
Aminian A, Kermansaravi M, Azizi S, Alibeigi P, Safamanesh S, Mousavimaleki A, Rezaei MT, Faridi M, Mokhber S, Pazouki A, Safari S. Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak. Obes Surg. 2020 Sep;30(9):3624-3627. doi: 10.100 — View Citation
Brindle ME, Gawande A. Managing COVID-19 in Surgical Systems. Ann Surg. 2020 Jul;272(1):e1-e2. doi: 10.1097/SLA.0000000000003923. — View Citation
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ — View Citation
Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020 May;17(5):268-270. doi: 10.1038/s41571-020-0362-6. — View Citation
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 20 — View Citation
Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, Zhan LY, Jia Y, Zhang L, Liu D, Xia ZY, Xia Z. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5;21:100331. — View Citation
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, — View Citation
Luong-Nguyen M, Hermand H, Abdalla S, Cabrit N, Hobeika C, Brouquet A, Goéré D, Sauvanet A. Nosocomial infection with SARS-Cov-2 within Departments of Digestive Surgery. J Visc Surg. 2020 Jun;157(3S1):S13-S18. doi: 10.1016/j.jviscsurg.2020.04.016. Epub 20 — View Citation
Wong SCY, Kwong RT, Wu TC, Chan JWM, Chu MY, Lee SY, Wong HY, Lung DC. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong. J Hosp Infect. 2020 Jun;105(2):119-127. doi: 10.1016/j.jhin.2020.03.0 — View Citation
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub — View Citation
Yang S, Zhang Y, Cai J, Wang Z. Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records. Oncologist. 2020 Jun;25(6):e982-e985. doi: 10.1634/theoncologist.2020-0157. Epub 2020 Apr 7. — View Citation
Zhong Q, Liu YY, Luo Q, Zou YF, Jiang HX, Li H, Zhang JJ, Li Z, Yang X, Ma M, Tang LJ, Chen YY, Zheng F, Ke JJ, Zhang ZZ. Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | COVID-19 Test Conversion | Patients that have negative pre-operative testing that convert to positive testing 14 days post-discharge | 14 days | |
Secondary | Duration of Hospitalization | Days from hospital admission to discharge. | 14 days | |
Secondary | Rate of self-reported COVID-19 exposure | Patients will be asked to describe if they have had any exposure to COVID-19 positive persons after their hospital stay. | 14 days | |
Secondary | Rate of complications from COVID-19 | If patients contract COVID-19 during the postoperative period, what complications occur? | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04446065 -
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
|
Phase 2/Phase 3 | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT04463004 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
Recruiting |
NCT04581148 -
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
|
||
Recruiting |
NCT04441372 -
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
|
||
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Completed |
NCT04530604 -
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
|
Phase 1 | |
Active, not recruiting |
NCT04635605 -
Methylene Blue Treatment of COVID-19
|
Phase 2 | |
Recruiting |
NCT04395599 -
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
|
N/A | |
Recruiting |
NCT04472585 -
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04411433 -
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
|
Phase 3 | |
Completed |
NCT04359706 -
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
|
||
Recruiting |
NCT04395794 -
SARS-CoV-2 Disguise Study
|
||
Completed |
NCT04386551 -
Detection of COVID-19 in Saliva Collection
|
||
Recruiting |
NCT04403269 -
NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE
|
Phase 2 | |
Withdrawn |
NCT04379492 -
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
|
Phase 2 | |
Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|